Genetic variants mimicking SGLT2 inhibition represent lifelong effects, yet they may not reflect the short-term clinical impacts or the gradual development of conditions like PAD and lower limb ulcers. This evidence concerns the gene SLC5A2 and peripheral arterial disease.